Fetuin-A protects against atherosclerotic calcification in CKD

Area of Science:

• Biochemistry
• Cardiovascular Science
• Nephrology

Background:

• Reduced serum fetuin-A correlates with cardiovascular mortality in dialysis patients.
• Fetuin-A deficiency in mice prevents vascular calcification, possibly due to endothelial protection.

Purpose of the Study:

• To investigate the role of fetuin-A in vascular calcification within an atherosclerosis model.
• To determine if fetuin-A deficiency exacerbates calcification in the presence of atherosclerosis, chronic kidney disease, and hyperphosphatemia.

Main Methods:

• Generated and compared fetuin-A/apolipoprotein E (ApoE)-deficient mice with ApoE-deficient and wild-type mice.
• Administered standard diet, high-phosphate diet, or unilateral nephrectomy plus high-phosphate diet for 9 weeks.
• Assessed atheroma formation, lipid deposition, neointima formation, coronary sclerosis, and extraosseous calcification.

Main Results:

• Fetuin-A deficiency, combined with hyperphosphatemia and CKD, increased vascular calcification 15-fold in ApoE-deficient mice.
• Fetuin-A deficiency promoted intimal rather than medial calcification in atherosclerotic lesions.
• High-phosphate diet and CKD increased valvular and myocardial calcification, with fetuin-A/ApoE deficiency showing the highest incidence.

Conclusions:

• Fetuin-A inhibits pathological calcification in soft tissues and vasculature, even during atherosclerosis.
• The interplay of fetuin-A deficiency, hyperphosphatemia, and CKD significantly drives vascular calcification.
• Therapeutic strategies targeting fetuin-A may be beneficial in preventing calcification in cardiovascular and kidney disease patients.